Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
QuintilesIMS
Baxter
Healthtrust
McKinsey
Daiichi Sankyo
Moodys
Chubb
Cerilliant
McKesson

Generated: February 20, 2018

DrugPatentWatch Database Preview

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) Drug Profile

« Back to Dashboard

When do Doxorubicin Hydrochloride (liposomal) patents expire, and when can generic versions of Doxorubicin Hydrochloride (liposomal) launch?

Doxorubicin Hydrochloride (liposomal) is a drug marketed by Dr Reddys Labs Ltd and Sun Pharma Global and is included in two NDAs.

The generic ingredient in DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.
Drug patent expirations by year for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Pharmacology for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Medical Subject Heading (MeSH) Categories for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

US Patents and Regulatory Information for DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Ltd DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 208657-001 May 15, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sun Pharma Global DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 203263-002 Feb 4, 2013 AB RX No Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Dr Reddys Labs Ltd DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 208657-002 May 15, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sun Pharma Global DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 203263-001 Feb 4, 2013 AB RX No Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Accenture
McKinsey
Express Scripts
Cantor Fitzgerald
Teva
Argus Health
Chubb
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot